Acute promyelocytic leukaemia (APL) in a patient with Crohn's disease and exposure to infliximab: a rare clinical presentation and review of the literature.
With the introduction of potent immunosuppressive and chemotherapeutic medications for various diseases, there is an increased incidence of therapy-related myeloid neoplasms. They are the result of mutational rearrangement and historically, have a grave prognosis compared with de novo myeloid neoplasms. We did a short review on various types of myeloid leukaemias reported after therapy with antitumour necrosis factor and also report, to the best of our knowledge, one among the very few cases of therapy-related acute promyelocytic leukaemia in a patient on infliximab therapy for refractory Crohn's disease. The patient responded well to the traditional treatment and is in complete remission for more than 5 years.
Department of Medicine/Hematology-Oncology, Staten Island University Hospital, Staten Island, New York, USA.
Farhan
F
Mohammad
Department of Medicine/Hematology-Oncology, Staten Island University Hospital, Staten Island, New York, USA.
Abhirami
A
Vivekanandarajah
Department of Medicine/Hematology-Oncology, Staten Island University Hospital, Staten Island, New York, USA.
Housam
H
Haddad
Department of Pathology, Staten Island University Hospital, Staten Island, New York, USA.
Christopher M
CM
Shutty
Department of Pathology, Staten Island University Hospital, Staten Island, New York, USA.
Matthew T
MT
Hurford
Department of Medicine/Hematology-Oncology, Staten Island University Hospital, Staten Island, New York, USA.
Qun
Q
Dai
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001707:Biopsy, Needle; D001856:Bone Marrow Examination; D003424:Crohn Disease / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D000069285:Infliximab; D015473:Leukemia, Promyelocytic, Acute / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology*; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D000069285:Infliximab